Skip to content
中文EN

Cardiometabolic

GLP-1 and obesity, Lp(a), heart failure and arrhythmia — pivotal trials and industry shape.

260 picksRelatedClinical readoutsDeals & financingNucleic acid drugs

Latest picks

41–60 of 260
Oct 10Sat
  1. Nature80

    Dynamics of human cardiogenesis and its disruption in trisomy 21.

    A spatially resolved single-cell multiomics map of the developing human heart defines 21 tissue niches, resolves three pacemaker cell subtypes in the sinoatrial node, and traces maturation trajectories of atrial and ventricular cardiomyocytes. Trisomy 21 hearts show depletion of compact cardiomyocytes and increased apoptosis relative to euploid hearts, a finding validated in isogenic-matched induced pluripotent stem cell-derived cardiomyocytes, providing a mechanistic lead on congenital heart disease risk in Down's syndrome.

    Why it matters: It links a cellular deficit in trisomy 21 hearts to congenital heart disease risk using a spatial human cardiac development atlas.

  2. WeChat71

    NMPA Approves Bairui Medical's Transcatheter Pulmonary Valve System

    China's National Medical Products Administration has approved the innovative device registration application of Beijing Bairui Medical Technology's transcatheter pulmonary valve system, filed by Beijing Bairui Medical Technology Co., Ltd. The system, comprising a delivery system with a conveyor and a loader, is placed via a small transthoracic incision. It is indicated for patients aged 9 or older weighing at least 20 kg with severe pulmonary regurgitation and a native right ventricular outflow tract after surgery for complex congenital heart disease.

    Why it matters: NMPA approval of a novel transcatheter pulmonary valve adds a minimally invasive option for post-surgical congenital heart disease patients.

  3. Medical Xpress52

    Lab-grown blood vessels reveal roles of different cells in rapid-aging disease

    A three-layer tissue-engineered human blood vessel model combining endothelial cells, smooth muscle cells and fibroblasts shows that different cell types drive distinct features of Hutchinson-Gilford progeria syndrome (HGPS) in the vasculature. Smooth muscle cells contributed to collagen accumulation, endothelial cells to inflammation, and HGPS fibroblasts substantially increased extracellular matrix changes, fibrotic signaling and vessel stiffness. CRISPR correction of the disease mutation returned many disease characteristics toward healthy levels.

    Why it matters: It separates cell-type-specific contributions to HGPS vascular disease and shows CRISPR correction effects in a human vessel model.

  4. Medical Xpress69

    Enzyme inhibitor limits scarring after heart attacks and protects heart function in mice

    Blocking the enzyme BCAT1, which supplies proline for collagen production in cardiac myofibroblasts, reduced scarring and preserved heart function in mice after a heart attack. The inhibitor ERG240 worked even when treatment began seven days after injury. Human heart tissue from patients with heart failure showed elevated BCAT1 linked to increased fibrosis, and BCAT1 was also raised in livers of patients with fatty liver disease.

    Why it matters: It identifies a druggable enzyme behind cardiac fibrosis and shows an inhibitor works when given after injury in mice.

  5. WeChat80

    Roche's Enicepatide 24 mg Shows 48-Week Weight Loss and Glucose Data Benchmarked Against Tirzepatide

    Roche has reported 48-week clinical data for enicepatide, its once-weekly GLP-1/GIP dual receptor agonist, at the 24 mg dose. In patients with type 2 diabetes, HbA1c fell by an average of 2.65 percentage points and weight by 15.5%. In overweight or obese patients without type 2 diabetes, mean weight loss was 22.7%, with 47.8% losing at least 20% and 26.1% at least 30%. The article discusses these results against tirzepatide, noting the two-residue difference between the molecules.

    Why it matters: The brief gives 24 mg 48-week weight and HbA1c reductions that allow comparison with tirzepatide in the same dose range.

  6. WeChat82

    RAY1225 Cuts Weight 22.24% at 52 Weeks in Phase III, Beating BGM0504's 19.2%

    RAY1225 injection, from Zhongsheng Pharmaceutical, met the primary endpoint in its Phase III weight-loss trial, with the 9 mg group losing 22.24% of baseline body weight over 52 weeks. Days earlier at EASD 2026, Borui Pharmaceutical's BGM0504 reported full Phase III data, with its 15 mg group losing 19.2% over 52 weeks. The two domestic GLP-1 candidates now post headline results exceeding the levels shown here for established comparators.

    Why it matters: Two Chinese obesity drug candidates report competing Phase III weight-loss results within one week.

Oct 9Fri
  1. WeChat68

    Oral GLP-1 Agonist Safiglipron Improves Glycemic Control in Phase 3 OUTSTAND-1 Trial

    The oral small-molecule GLP-1 receptor agonist safiglipron (HRS-7535), developed by Hengrui Pharmaceuticals and taken once daily without fasting or dietary restrictions, significantly improved glycemic control as monotherapy in patients with early type 2 diabetes in the phase 3 OUTSTAND-1 trial. Higher doses also produced weight benefits, and improvements were observed in islet function and multiple cardiometabolic and cardiorenal metabolic markers. The results were published in Nature Medicine.

    Why it matters: Phase 3 data on a once-daily oral GLP-1 receptor agonist offer an injection-free option for type 2 diabetes.

  2. BioSpace54

    TRexBio, Retension raise $161.7M in IPOs; City, Iambic set proposed offering terms

    TRexBio raised $116.7 million in its Nasdaq IPO, selling 8.3 million shares at $14 to fund TRB-061, a fusion protein in early-stage development for atopic dermatitis with a Phase 1b topline readout expected mid-2027. Retension Pharmaceuticals raised $45 million at $12 per share to advance RTN-001, a PDE-5 blocker for hypertension, through Phase 2b and into Phase 3. City Therapeutics expects about $158.3 million and Iambic Therapeutics about $135 million from upcoming offerings.

    Why it matters: Four biotech IPOs in one week signal a reopening of the public markets for drug developers.

  3. Nature74

    A gut microbial odd-chain fatty acid alleviates atherosclerosis in mice.

    Pentadecanoic acid (PA, C15:0), an odd-chain fatty acid produced by Bacteroides uniformis and other Bacteroidota, alleviates atherosclerosis in mice. PA supplementation cut atherosclerotic plaque burden by around 50% and improved plasma lipid profiles by inhibiting HMG-CoA reductase, suppressing hepatic cholesterol biosynthesis and promoting LDL cholesterol removal via upregulation of hepatic LDL receptor. PA is markedly depleted in patients with dyslipidaemia.

    Why it matters: Identifies a specific microbiota-derived metabolite with a mechanism and roughly 50% plaque reduction in mice.

  4. Cell77

    Immunoregulatory gene GIMAP6 suppresses lethal atherosclerotic vasculopathy and ischemic heart failure.

    Loss of the immunoregulatory gene Gimap6 in mice causes inflammatory vasculopathy and accelerated atherosclerosis without hyperlipidemia, leading to cardiac ischemia, myocardial infarction, heart failure, and early death. Mechanistically, GIMAP6 loss triggers endothelial barrier failure and a mitochondrial ROS-PPARγ-CD36 lipid-influx cascade that promotes foam-cell formation and IL-6/MCP-1/TNF inflammation. Human hypomorphic GIMAP6 variants, including the African-ancestry-enriched V65I allele, are associated with increased CD36-mediated lipid uptake and early ASCVD.

    Why it matters: Identifies a lipid-independent genetic route to lethal atherosclerosis with a corresponding human risk allele.

  5. WeChat73

    FDA Approves Bristol Myers Squibb's Mavacamten for Symptomatic Obstructive HCM in Patients Weighing 30 kg or More

    The FDA has approved Bristol Myers Squibb's mavacamten to improve functional capacity and symptoms in children and adults weighing 30 kg (66 lb) or more who have symptomatic obstructive hypertrophic cardiomyopathy (oHCM). The approval is based on positive results from the Phase 3 SCOUT-HCM trial and extends the drug's existing clinical evidence in adult oHCM. Mavacamten is the only FDA-approved drug for pediatric oHCM.

    Why it matters: First FDA approval extending mavacamten, the only approved pediatric oHCM drug, to children.

  6. WeChat77

    NMPA Approves Beijing Bailian Medical's Transcatheter Pulmonary Valve System

    China's National Medical Products Administration has approved the innovative device registration application for the transcatheter pulmonary valve system of Beijing Bailian Medical Technology. The system, comprising a delivery system with a delivery catheter and loader, is placed via a small transthoracic incision. It is indicated for patients aged at least 9 years and weighing at least 20 kg with severe pulmonary regurgitation and a native right ventricular outflow tract after surgery for complex congenital heart disease.

    Why it matters: NMPA approval of a domestically developed transcatheter pulmonary valve adds a new interventional option for post-surgical congenital heart disease patients.

Oct 8Thu
  1. Cell73

    Immunoregulatory gene GIMAP6 suppresses lethal atherosclerotic vasculopathy and ischemic heart failure

    Loss of the immunoregulatory gene GIMAP6 drives atherosclerosis and ischemic heart disease by destabilizing the endothelium and promoting macrophage lipid loading and inflammation. The mechanism operates without hyperlipidemia, though hyperlipidemia significantly worsens disease progression. The work identifies GIMAP6 as a suppressor of lethal atherosclerotic vasculopathy and ischemic heart failure, adding a lipid-independent route to disease.

    Why it matters: It identifies a gene-driven, lipid-independent mechanism of atherosclerosis and ischemic heart failure.

  2. BioSpace61

    Despite Zealand asset’s ‘intriguing’ weight loss, analysts underwhelmed by blood sugar numbers

    Petrelintide, Zealand Pharma's Roche-partnered long-acting amylin analog, met its primary weight-loss endpoint in the Phase 2 ZUPREME-2 trial. Among 220 patients with obesity or overweight and T2D, the drug achieved up to 9.2% mean weight loss at week 28, versus 2% for placebo.

    Why it matters: Gives petrelintide's 9.2% weight loss and 0.65% A1C reduction in ZUPREME-2, against 1.3%-2.1% for eloralintide and Zepbound, enabling direct comparison.

  3. WeChat78

    Retatrutide Delivers Over 20 Percent Weight Loss and Normal Glucose in 40 Percent of Patients at 80 Weeks in TRIUMPH-2

    Retatrutide, a first-in-class triple-target hormone receptor agonist, produced clinically meaningful weight loss and improved glycemic control over 80 weeks in adults with obesity or overweight and type 2 diabetes in the TRIUMPH-2 trial, with additional benefits on multiple cardiovascular risk factors. Data were presented at the 62nd EASD meeting in Milan and published in The Lancet.

    Why it matters: Phase 3 results of a first-in-class triple agonist in a major obesity-with-diabetes population, published in The Lancet.

Oct 7Wed
  1. Nature78

    A gut microbial odd-chain fatty acid alleviates atherosclerosis in mice

    The paper reports that a gut microbial odd-chain fatty acid alleviates atherosclerosis in mice. The work draws on mouse experiments together with human gut metagenomic datasets from atherosclerotic cardiovascular disease and subclinical carotid atherosclerosis cohorts, and includes RNA-seq data and molecular docking against the human HMGCR structure.

    Why it matters: Links a gut microbial metabolite to atherosclerosis outcomes in mice, with human metagenomic support.

  2. WeChat67

    SMARTEST Trial Finds Dapagliflozin No Better Than Metformin in Early Type 2 Diabetes

    The SMARTEST randomized trial, presented at the EASD annual meeting in Milan, found that starting dapagliflozin directly was no better than metformin at reducing long-term complications in patients with early type 2 diabetes and no evident cardiovascular or kidney disease. The result challenges the assumption that newly diagnosed patients must begin with metformin, though it offers no basis for preferring dapagliflozin as first-line therapy.

    Why it matters: Head-to-head trial data on first-line drug choice for early type 2 diabetes directly informs prescribing practice.

  3. Nature Biotechnology63

    Decoding systemic vascular health and hypertensive disorders in pregnancy through retinal imaging and Visionary AI.

    Visionary AI, a platform combining retinal imaging with graph-based vascular modeling, predicted hypertensive disorders of pregnancy before clinical onset. In a prospective development cohort of 1,267 pregnancies it reached AUC 0.91 and average precision 0.81 for preeclampsia, and a stability-optimized model transferred without retraining to external validation at AUC 0.81 and AP 0.68, outperforming clinical and deep learning benchmarks. The finding positions the maternal retina as a minimally invasive biosensor for first-trimester risk stratification.

    Why it matters: First-trimester preeclampsia prediction from retinal images outperformed clinical and deep learning benchmarks in external validation.

  4. WeChat81

    Retatrutide Phase III Results Appear in NEJM and The Lancet as Nearly a Quarter With Obesity Lose Over 35% of Body Weight

    Retatrutide, the first triple hormone receptor agonist to complete Phase III with key efficacy data, was published in NEJM and The Lancet on the same day. The Eli Lilly drug activates GIP, GLP-1 and glucagon receptors in a single molecule and is given as a once-weekly subcutaneous injection. Nearly a quarter of participants with obesity lost more than 35% of their body weight.

    Why it matters: First Phase III efficacy readout for a triple agonist, published simultaneously in NEJM and The Lancet.

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org